Esketamine use in real-world clinical practice in patients with treatment-resistant depression.
European psychiatry : the journal of the Association of European Psychiatrists August 26, 2025 Ismaël Conejero, Raquel Alvarez García, Alejandro Porras-Segovia et al. 2 citations
Esketamine has been shown to produce a major antidepressant response in patients with treatment-resistant depression (TRD). We evaluated the factors associated with achieving remission in these individuals. The study was carried out across four psychiatry departments in Madrid, Spain. Patients aged over 18 years were included if they received esketamine as an augmentation treatment for TRD....